Full Press Release Details
TherapeuticsMD, Inc. 8-K
Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
Leading Healthcare Investor Will Provide TherapeuticsMD with Strategic Growth Capital -
Additional Non-Dilutive Funding Will Support the Launches of BIJUVATM and ANNOVERATM -
RATON, Fla., April 17, 2019 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company,
today announced that it has signed a binding commitment letter for a fully-negotiated $300 million non-dilutive secured term loan
financing facility with TPG Sixth Street Partners ("TSSP"), the global finance and investment business in strategic
partnership with TPG, the global alternative asset firm.
TSSP term loan facility will be available to the company in three tranches:
| $200 million will be immediately available upon the closing of the facility; | ||
| $50 million will be available upon the designation of ANNOVERA as a new category of birth control by the U.S. Food and Drug Administration on or prior to December 31, 2019; and | ||
| $50 million will be available upon TherapeuticsMD achieving $11 million in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019 |
anticipates that the TSSP term loan facility will close on or before May 10, 2019, subject to the satisfaction of certain customary
conditions precedent.
under the TSSP term loan facility will accrue interest at 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70%. Interest
on amounts borrowed under the facility will be payable quarterly. The outstanding principal amount of the term loan facility will
be payable in four equal quarterly installments beginning on June 30, 2023, with the term loan facility maturing on March 31,
are very pleased with the flexible terms of our new facility with TPG Sixth Street Partners," said Robert G. Finizio, CEO
of TherapeuticsMD. "This facility will allow us to continue our growth strategy as we focus on the commercial launch of
BIJUVA and prepare for the launch of ANNOVERA later this year. This financing demonstrates the confidence that our new lenders
have in our business and also further strengthens our balance sheet without any dilution in equity."
has notified its existing lender, MidCap Financial Trust, managed by Apollo Capital Management, L.P., that the company will be
terminating its existing term loan credit and security agreement. A portion of the initial tranche of the
new TSSP facility will be used to repay amounts outstanding under the company's existing term loan credit and security agreement
with MidCap Financial Trust.
will host a conference call today to discuss the financing transaction and the launch of BIJUVA.
Details for the call are:
Access (International):
Code for All Callers:
TPG Sixth Street Partners (TSSP)
Sixth Street Partners (TSSP) is a global finance and investment business with over $30 billion in assets under management. Co-founded
in 2009 by Managing Partner Alan Waxman and TSSP's management team, the firm's long-term oriented, highly flexible
capital base allows it to invest across industries, geographies, capital structures and asset classes. TSSP focuses on partnering
with businesses and management teams to create fully committed financing solutions. TSSP is in a strategic partnership with
TPG, the global alternative asset firm. For more information, visit www.tssp.com.
About TherapeuticsMD,
Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for
women. Our products are designed to address the unique changes and challenges women experience
through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management.
The company is committed to advancing the health of women and championing awareness of their
and on Facebook: TherapeuticsMD.
press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements,
other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes
or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes,"
"hopes," "may," "anticipates," "should," "intends," "plans,"
"will," "expects," "estimates," "projects," "positioned," "strategy"
and similar expressions and are based on assumptions and assessments made in light of management's experience and perception
of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are
not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's
control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in the company's filings with the Securities
and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports
on Form 8-K, and include the following: the company's ability to maintain or increase sales of its products; the company's
ability to develop and commercialize IMVEXXY , ANNOVERA , BIJUVA and its hormone
therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to close its term
loan facility with TSSP and thereafter will be able to comply with the covenants and conditions under such term loan facility;
the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company's
current or future approved products or preclude the approval of the company's future drug candidates; the length, cost and
uncertain results of future clinical trials; the company's reliance on third parties to conduct its manufacturing, research
and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies
for the company's products; the impact of product liability lawsuits; the influence of extensive and costly government regulation;
the volatility of the trading price of the company's common stock and the concentration of power in its stock ownership.
PDF copies of the company's historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
President, Investor Relations